Introduction
T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy arising from T-cell progenitors, accounts for ~15% of ALL cases in children and ~25% in adults. The long-term survival rate for children and adolescents with this disease is 70-75%, while for adults the rate is only 35-40% in Western populations (1) . Over 50% of patients with T-ALL harbor activation mutations of Notch1 (2), thus, γ-secretase inhibitors, which block Notch signaling, were a promising target for therapy. However, associated problems, such as limited therapeutic benefit and intestinal toxicity have since been reported (3) . Therefore, there is a requirement for the development of novel and effective treatment strategies for adult T-ALL.
Notch1 mutations mainly involve the heterodimerization domain (HD) and the proline, glutamic acid, serine, threonine-rich domain (PEST) (2) . The HD mutation results in ligand-independent proteolytic cleavage of Notch1, while the PEST mutation blocks Fbw7 interaction with Notch1 and, thereby, prevents its polyubiquitination and degradation (3, 4) . The mutations of these two domains result in constitutive activation of the Notch signaling pathway (1) . Moreover, ~30% of T-ALL patients harbor inactivating mutations of the Fbw7 gene, which also activate Notch1 signaling (1) . It has been demonstrated that c-Myc is a direct and important target gene of Notch1, and its expression levels have been observed to increase along with activation of Notch1 signaling in T-ALL (5). In addition, a previous study showed that the half-life of c-Myc in B-cell or T-cell ALL was markedly prolonged (6) . Therefore, c-Myc may be a target for therapy in T-ALL.
Valproic acid (VPA), a histone deacetylase inhibitor (HDACI), has been reported to treat various hematological malignancies (7) (8) (9) . Previous studies revealed that VPA was more efficacious in combination with other agents, such as idarubicin, 5-azacitidina and all-trans retinoic acid (10-12). In acute myeloid leukemia (AML), VPA inhibited cell growth, mainly by downregulation of c-Myc expression (13) . However, the role of c-Myc in the growth inhibition of T-ALL cells induced by VPA remains unclear. We hypothesized that its role in T-ALL was the same as that in AML, and that a c-Myc inhibitor would be able to augment the anti-leukemic effect of VPA. In the present study, the effect of VPA combined with a c-Myc inhibitor (10058-F4) on T-ALL cell lines (Jurkat and CCRF-CEM cells) was investigated.
Materials and methods
Cell lines and reagents. T-ALL cell lines, Jurkat and CCRF-CEM cells, were purchased from the American Type Culture Collection (Manassas, VA, USA). These cells were maintained in RPMI-1640 (Gibco-BRL, Grand Island, NY, USA) supplemented with heat-inactivated fetal bovine serum (Gibco-BRL) at 37˚C in a 5% CO 2 humidified incubator. VPA and 10058-F4 (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in dimethylsulfoxide (DMSO) at 1 M and 20 mM and then stored at -20˚C in small aliquots. Z-VAD-FMK (Sigma-Aldrich), a pan-caspase inhibitor (14) , was also dissolved in DMSO and its final concentration was 20 µM.
Cell viability assay. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) assay. Briefly, cells were seeded in 96-well plates and treated with VPA (0-3.2 mM), alone or in combination with 60 µM 10058-F4, for 24 h. In each well, MTT solution (final concentration, 0.5 mg/ml) was added and the cells were then incubated at 37˚C for 4 h. The absorbance value of each well was measured by a spectrophotometry at 570 nm. 
Quantitative polymerase chain reaction (qPCR).
The expression level of the c-MYC gene was determined using reverse transcription-qPCR with SYBR Green Ⅰ [Takara Biotechnology (Dalian) Co., Ltd., Dalian, China], and GAPDH was used as a reference gene. Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) and reverse transcribed into cDNA by a SuperScript Ⅱ first-strand cDNA synthesis kit (Invitrogen Life Technologies). The reaction system contained 12.5 µl 2X SYBR Premix Ex Taq [Takara Biotechnology (Dalian) Co., Ltd.], 1 µl cDNAs and 10 pmol of each primer. The primer sequences were as follows: Forward, 5'-ATGGGGAAGGTGAAGGTCG-3' and reverse, 5'-GGGTCATTGATGGCAACAATATC-3' for GAPDH; and forward, 5'-CGTCTCCACACATCAGCACAA-3' and reverse, 5'-CACTGTCCAACTTGACCCTCTTG-3' for c-MYC. The reaction was performed at 95˚C for 1 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and annealing/extension at 60˚C for 60 sec, on an iQ5 Real-Time PCR instrument (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Western blot. Jurkat and CCRF-CEM cells were lysed at 0˚C in lysis buffer for 30 min, and their protein concentrations were measured by the Bradford protein assay method. The samples were separated by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride (PVDF) membranes. PVDF membranes were blocked with Tris-buffered saline containing 0.1% Tween (TBST; prepared in the laboratory, Department of Hematology, Institute of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China) and 5% non-fat milk for 2 h at room temperature. The membranes were then incubated with the primary antibodies, rabbit anti-human monoclonal c-Myc (D84C12 XP ® ), rabbit anti-human monoclonal caspase-3 (8G10) and mouse antihuman monoclonal β-actin (8H10D10) (dilution, 1:1000-5000; Cell Signaling Technology, Beverly, MA, USA), overnight at 4˚C. Following washing four times for 10 min each time with TBST, these PVDF membranes were incubated with the goat anti-rabbit (catalogue number, 7074) or horse anti-mouse (catalogue number, 7076) IgG horseradish peroxidase-conjugated secondary antibodies (dilution, 1:2000; Cell Signaling Technology) for 2 h at room temperature. The membranes were again washed four times with TBST, and protein bands were then visualized with the enhanced chemiluminescence detecting kit (EZ-ECL chemiluminescence detection kit; Biological Industries, Beit-Haemek, Israel) and exposed to X-ray films.
Statistical analysis. The significant differences between experimental and control groups were compared by Student's t-test. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
Results

VPA downregulates the expression of c-Myc in Jurkat and
CCRF-CEM cells. First, the role of c-Myc in the growth inhibition of T-ALL cells induced by VPA was identified. Western blots revealed that after Jurkat and CCRF-CEM cells were treated with VPA at various concentrations for 24 h, the expression of c-Myc protein was markedly downregulated in a dose-dependent manner, and was accompanied by cleavage of caspase-3 (Fig. 1A) . qPCR was then performed to measure the c-Myc mRNA levels, and it was found that the expression of c-Myc was also decreased in Jurkat and CCRF-CEM cells treated with 0.8 mM VPA for 24 h (Fig. 1B; P<0 .01), indicating that c-Myc was downregulated at a transcriptional level. In addition, decreased expression of c-Myc protein in a time-dependent manner was observed in Jurkat cells (Fig. 1C) , but not examined in CCRF-CEM cells.
10058-F4 further promotes downregulation of c-Myc expression by VPA.
It has been demonstrated that 10058-F4 can block the dimerization of c-Myc and Max, and then inhibit c-Myc transactivating activity (15) . Thus, we hypothesized that 10058-F4 promotes the downregulation of c-Myc expression induced by VPA. The western blotting results showed that c-Myc expression levels in Jurkat and CCRF-CEM cells treated with VPA (0, 0.8 and 1.6 mM) combined with 60 µM 10058-F4 decreased further compared with the corresponding controls (Fig. 2) . (Fig. 3) .
10058-F4 increases the growth inhibition of Jurkat and CCRF-CEM cells induced by VPA. c-Myc is an important oncogene, which contributes to the growth of T-ALL cells, particularly T-ALL cells with Notch1 mutations (5)
.
10058-F4 markedly increases the cell death induced by VPA in a caspase-dependent and -independent manner.
Previous studies have demonstrated that 10058-F4 efficiently induced cell death in myeloma and AML cells (15, 16) . Concordant with this, cell death of Jurkat and CCRF-CEM cells treated with VPA (0, 0.8, 1.6 and 2.4 mM) was increased when combined with 10058-F4. As shown in Fig. 4A , compared with treatment with corresponding concentrations of VPA alone, cell death rates (Annexin V + /PI + and Annexin V + /PI -) of Jurkat and CCRF-CEM cells treated with 10058-F4 combined with VPA increased significantly (P=0.038 and P=0.037, respectively). In addition, western blot analysis revealed that 10058-F4 could promote the cleavage of caspase-3 induced by VPA (Fig. 4B) . The results also demonstrated that Z-VAD-FMK, a pan-caspase inhibitor, could partially inhibit cell death of Jurkat cells induced by 10058-F4 combined with VPA (72.33±3.35 vs. 37.4±1.87%, P<0.001) (Fig. 4C) . These findings indicate that 10058-F4 dramatically increases cell death induced by VPA through caspase-dependent and -independent pathways.
Discussion
It has been demonstrated that VPA could prevent growth of cancer cells by inducing apoptosis and cell cycle arrest, and by promoting cellular differentiation (17) . HDACIs, including VPA, can selectively alter the expression levels of a relatively small proportion of genes by recovering the deacetylation of histones (18) . Regarding these genes in which the expression levels are altered by HDACIs, upregulation of the surface TRAIL death receptors (DR4 and DR5) in multiple myeloma (19) , upregulation of p21 and p27 in mantle cell lymphoma (20) , and downregulation of c-Myc in AML and endometrial cancer cells (13, 21) played a key role in the induction of apoptosis and cell cycle arrest or the promotion of cellular differentiation. Since activating mutations of Notch1 were observed in >50% T-ALL patients (3) and c-Myc is an important direct target of Notch1 (5), the present study examined whether c-Myc was downregulated in the growth inhibition of T-ALL cells induced by VPA. The results showed that, as in AML (13), c-Myc expression was markedly downregulated in Jurkat and CCRF-CEM cells in which activation of Notch1 signaling occurred (22) . Further investigation revealed that 10058-F4 could reinforce the downregulation of c-Myc induced by VPA, indicating that the former may increase the sensitivity to the latter.
Previous studies have demonstrated that VPA can induce apoptosis in leukemic cells (7, 23) . Notably, VPA also augmented apoptosis of leukemic cells induced by other agents, such as A B C cytarabine (24), etoposide (25) and bortezomib (26) . Thus, the present study next examined the cell death of Jurkat and CCRF-CEM cells induced by VPA combined with 10058-F4. The results showed that 10058-F4 could markedly increase the cell death of Jurkat and CCRF-CEM cells induced by VPA (0, 0.8, 1.6 and 2.4 mM). Activation of caspase-3 also increased correspondingly. However, Z-VAD-FMK partially inhibited the cell death induced by 10058-F4 combined with VPA, indicating that their apoptotic effects involved in both caspase-dependent and -independent pathways. Previous studies have also demonstrated that not only 10058-F4, but also VPA, induced apoptosis through both caspase-dependent and -independent pathways (15, 23, 27) . Although there have been arguments for and against the therapeutic targeting of Myc (28) , recent experiments in vivo and in vitro have demonstrated that it is a promising therapeutic strategy in high-risk hematologic malignancies (29, 30) . The present study showed that downregulation of c-Myc by 10058-F4 markedly increased VPA-induced apoptosis. These findings suggest that VPA combined with c-Myc inhibitors may be a novel potent therapeutic strategy for adult T-ALL patients. However, further investigation with regard to the clinical effect of their combination is required in the future.
